Condition
Stereotactic Body Radiation Therapy
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 6 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
6 shownSTART-MET HS Prostate Cancer. : SbrT & Androgen Receptor Therapy METastatic HSPCNCT05209243 · 2023-01-26
RECRUITINGImpact of a Hypnotic Recording on Artifacts in 4D CT in the Context of Stereotactic Body Radiation Therapy for Lung CancerNCT07334990 · 2025-12-30
NOT_YET_RECRUITINGThe ctDNA for Evaluating Whether to Use Adjuvant Therapy After SBRT in Patients With Early Lung CancerNCT05411809 · 2022-06-15
NOT_YET_RECRUITINGShared Decision Making on Radiation Dose for Lung MalignanciesNCT04940936 · 2021-11-12
ACTIVE_NOT_RECRUITINGSurgery Versus Stereotactic Body Radiation Therapy for Stage up to IA2 (T1a or T1b) Non-small Cell Lung CancerNCT03431415 · 2018-01-28
WITHDRAWNStereotactic Radiosurgery Combination With Anlotinib for Limited Brain Metastases in NSCLCNCT04912128 · 2017-01-15
COMPLETEDCommon interventions
Leading sponsors
Trial status mix
NOT_YET_RECRUITING2
ACTIVE_NOT_RECRUITING1
COMPLETED1
RECRUITING1
WITHDRAWN1
Phase mix
NA5
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.